Raletić-Savić J, Zivanović A, Savić D
Medicinski fakultet, Novi Sad, Institut za onkologiju, Sremska Kamenica.
Arh Hig Rada Toksikol. 1991 Sep;42(3):295-301.
Patients undergoing chemotherapy or radiotherapy for malignancies often develop annoying inflammation of the oral mucosa as a side-effect of cytotoxic therapy. As prostaglandins are known to be cytoprotective Prostin E2 was given to 10 patients with neoplasms of the ear, nose, pharynx or larynx, or of the maxillofacial region, who received radiotherapy. The reference group was made up of five patients with the analogous diagnosis who received the conventional therapy with Hexoral sol. One patient was not administered any therapy. The patients that were given Prostin E2 did not develop either the inflammatory process or stomatitis. In the reference group the inflammatory process appeared in two patients and lesions were noticed in one patient. Excellent results, although still preliminary, pointed out that preventive local administration of Prostin E2 was superior to the conventional therapy and that accordingly, Prostin E2 should be regarded as the drug of choice.
接受恶性肿瘤化疗或放疗的患者常常会出现恼人的口腔黏膜炎症，这是细胞毒性治疗的副作用。由于已知前列腺素具有细胞保护作用，因此对10例接受放疗的耳、鼻、咽、喉或颌面区域肿瘤患者给予前列腺素E2。参照组由5例诊断类似但接受海克索口腔溶液常规治疗的患者组成。有1例患者未接受任何治疗。给予前列腺素E2的患者既未出现炎症过程，也未发生口腔炎。参照组中有2例患者出现炎症过程，1例患者出现病变。尽管结果仍属初步，但极佳的效果表明，预防性局部给予前列腺素E2优于常规治疗，因此，前列腺素E2应被视为首选药物。
